Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Immune Th17 lymphocytes play a critical role in the multiple beneficial properties of resveratrol.

Delmas D, Limagne E, Ghiringhelli F, Aires V.

Food Chem Toxicol. 2020 Mar;137:111091. doi: 10.1016/j.fct.2019.111091. Epub 2019 Dec 26.

PMID:
31883989
2.

Trifluridine/Tipiracil plus Oxaliplatin Improves PD-1 Blockade in Colorectal Cancer by Inducing Immunogenic Cell Death and Depleting Macrophages.

Limagne E, Thibaudin M, Nuttin L, Spill A, Derangère V, Fumet JD, Amellal N, Peranzoni E, Cattan V, Ghiringhelli F.

Cancer Immunol Res. 2019 Dec;7(12):1958-1969. doi: 10.1158/2326-6066.CIR-19-0228. Epub 2019 Oct 14.

PMID:
31611243
3.

Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination.

Grapin M, Richard C, Limagne E, Boidot R, Morgand V, Bertaut A, Derangere V, Laurent PA, Thibaudin M, Fumet JD, Crehange G, Ghiringhelli F, Mirjolet C.

J Immunother Cancer. 2019 Jun 25;7(1):160. doi: 10.1186/s40425-019-0634-9.

4.

Anti-MEK and Anti-EGFR mAbs in RAS-Mutant Metastatic Colorectal Cancer: Case Series and Rationale.

Ledys F, Derangère V, Réda M, Guion JF, Milliex R, Roux V, Limagne E, Arnould L, Bengrine L, Ghiringhelli F, Rébé C.

Adv Ther. 2019 Jun;36(6):1480-1484. doi: 10.1007/s12325-019-00949-y. Epub 2019 Apr 12.

PMID:
30980281
5.

Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients.

Limagne E, Richard C, Thibaudin M, Fumet JD, Truntzer C, Lagrange A, Favier L, Coudert B, Ghiringhelli F.

Oncoimmunology. 2019 Jan 22;8(4):e1564505. doi: 10.1080/2162402X.2018.1564505. eCollection 2019.

6.

Fluorouracil and bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): a single-arm phase 2 study.

Isambert N, Hervieu A, Rébé C, Hennequin A, Borg C, Zanetta S, Chevriaux A, Richard C, Derangère V, Limagne E, Blanc J, Bertaut A, Ghiringhelli F.

Oncoimmunology. 2018 Aug 1;7(9):e1474319. doi: 10.1080/2162402X.2018.1474319. eCollection 2018.

7.

Lysophosphatidylcholine acyltransferase 2-mediated lipid droplet production supports colorectal cancer chemoresistance.

Cotte AK, Aires V, Fredon M, Limagne E, Derangère V, Thibaudin M, Humblin E, Scagliarini A, de Barros JP, Hillon P, Ghiringhelli F, Delmas D.

Nat Commun. 2018 Jan 22;9(1):322. doi: 10.1038/s41467-017-02732-5.

8.

IRF8-dependent molecular complexes control the Th9 transcriptional program.

Humblin E, Thibaudin M, Chalmin F, Derangère V, Limagne E, Richard C, Flavell RA, Chevrier S, Ladoire S, Berger H, Boidot R, Apetoh L, Végran F, Ghiringhelli F.

Nat Commun. 2017 Dec 12;8(1):2085. doi: 10.1038/s41467-017-01070-w.

9.

Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer.

Kaderbhai CG, Richard C, Fumet JD, Aarnink A, Ortiz-Cuaran S, Pérol M, Foucher P, Coudert B, Favier L, Lagrange A, Limagne E, Boidot R, Ladoire S, Poudenx M, Ilie M, Hofman P, Saintigny P, Ghiringhelli F.

Oncoimmunology. 2017 Jun 16;6(9):e1339856. doi: 10.1080/2162402X.2017.1339856. eCollection 2017.

10.

Immune classifications with cytotoxic CD8+ and Th17 infiltrates are predictors of clinical prognosis in glioblastoma.

Madkouri R, Kaderbhai CG, Bertaut A, Truntzer C, Vincent J, Aubriot-Lorton MH, Farah W, Limagne E, Ladoire S, Boidot R, Derangère V, Ghiringhelli F.

Oncoimmunology. 2017 Apr 28;6(6):e1321186. doi: 10.1080/2162402X.2017.1321186. eCollection 2017.

11.

Trifluridine/Tipiracil combined to oxaliplatin sensitizes microsatellite stable colorectal cancer to anti-PD-1 blockade.

Limagne E, Nuttin L, Spill A, Thibaudin M, Derangere V, Cattan V, Bruno A, Amellal N, Ghiringhelli F.

Ann Oncol. 2017 Jun;28 Suppl 3:iii90. doi: 10.1093/annonc/mdx261.254. No abstract available.

12.

Antibiotic Use Does Not Appear to Influence Response to Nivolumab.

Kaderbhai C, Richard C, Fumet JD, Aarnink A, Foucher P, Coudert B, Favier L, Lagrange A, Limagne E, Boidot R, Ghiringhelli F.

Anticancer Res. 2017 Jun;37(6):3195-3200.

PMID:
28551664
13.

Sirtuin-1 Activation Controls Tumor Growth by Impeding Th17 Differentiation via STAT3 Deacetylation.

Limagne E, Thibaudin M, Euvrard R, Berger H, Chalons P, Végan F, Humblin E, Boidot R, Rébé C, Derangère V, Ladoire S, Apetoh L, Delmas D, Ghiringhelli F.

Cell Rep. 2017 Apr 25;19(4):746-759. doi: 10.1016/j.celrep.2017.04.004.

14.

Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX-Bevacizumab Drug Treatment Regimen.

Limagne E, Euvrard R, Thibaudin M, Rébé C, Derangère V, Chevriaux A, Boidot R, Végran F, Bonnefoy N, Vincent J, Bengrine-Lefevre L, Ladoire S, Delmas D, Apetoh L, Ghiringhelli F.

Cancer Res. 2016 Sep 15;76(18):5241-52. doi: 10.1158/0008-5472.CAN-15-3164. Epub 2016 Aug 5.

15.

Resveratrol Interferes with IL1-β-Induced Pro-Inflammatory Paracrine Interaction between Primary Chondrocytes and Macrophages.

Limagne E, Lançon A, Delmas D, Cherkaoui-Malki M, Latruffe N.

Nutrients. 2016 May 11;8(5). pii: E280. doi: 10.3390/nu8050280.

16.

Human ectonucleotidase-expressing CD25high Th17 cells accumulate in breast cancer tumors and exert immunosuppressive functions.

Thibaudin M, Chaix M, Boidot R, Végran F, Derangère V, Limagne E, Berger H, Ladoire S, Apetoh L, Ghiringhelli F.

Oncoimmunology. 2015 Jul 6;5(1):e1055444. eCollection 2016.

17.

Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?

Derangère V, Fumet JD, Boidot R, Bengrine L, Limagne E, Chevriaux A, Vincent J, Ladoire S, Apetoh L, Rébé C, Ghiringhelli F.

Oncotarget. 2016 Feb 23;7(8):9309-21. doi: 10.18632/oncotarget.7008.

18.

Corrigendum: The receptor NLRP3 is a transcriptional regulator of TH2 differentiation.

Bruchard M, Rebé C, Derangère V, Togbé D, Ryffel B, Boidot R, Humblin E, Hamman A, Chalmin F, Berger H, Chevriaux A, Limagne E, Apetoh L, Végran F, Ghiringhelli F.

Nat Immunol. 2015 Dec;16(12):1292. doi: 10.1038/ni1215-1292a. No abstract available.

PMID:
26580508
19.

The receptor NLRP3 is a transcriptional regulator of TH2 differentiation.

Bruchard M, Rebé C, Derangère V, Togbé D, Ryffel B, Boidot R, Humblin E, Hamman A, Chalmin F, Berger H, Chevriaux A, Limagne E, Apetoh L, Végran F, Ghiringhelli F.

Nat Immunol. 2015 Aug;16(8):859-70. doi: 10.1038/ni.3202. Epub 2015 Jun 22. Erratum in: Nat Immunol. 2015 Dec;16(12):1292.

PMID:
26098997
20.

Induction of oxiapoptophagy on 158N murine oligodendrocytes treated by 7-ketocholesterol-, 7β-hydroxycholesterol-, or 24(S)-hydroxycholesterol: Protective effects of α-tocopherol and docosahexaenoic acid (DHA; C22:6 n-3).

Nury T, Zarrouk A, Mackrill JJ, Samadi M, Durand P, Riedinger JM, Doria M, Vejux A, Limagne E, Delmas D, Prost M, Moreau T, Hammami M, Delage-Mourroux R, O'Brien NM, Lizard G.

Steroids. 2015 Jul;99(Pt B):194-203. doi: 10.1016/j.steroids.2015.02.003. Epub 2015 Feb 12.

PMID:
25683890
21.

The role of reactive oxygen species and subsequent DNA-damage response in the emergence of resistance towards resveratrol in colon cancer models.

Colin DJ, Limagne E, Ragot K, Lizard G, Ghiringhelli F, Solary É, Chauffert B, Latruffe N, Delmas D.

Cell Death Dis. 2014 Nov 20;5:e1533. doi: 10.1038/cddis.2014.486.

22.

Liver X receptor β activation induces pyroptosis of human and murine colon cancer cells.

Derangère V, Chevriaux A, Courtaut F, Bruchard M, Berger H, Chalmin F, Causse SZ, Limagne E, Végran F, Ladoire S, Simon B, Boireau W, Hichami A, Apetoh L, Mignot G, Ghiringhelli F, Rébé C.

Cell Death Differ. 2014 Dec;21(12):1914-24. doi: 10.1038/cdd.2014.117. Epub 2014 Aug 15.

23.

A role for peroxisome proliferator-activated receptor gamma in resveratrol-induced colon cancer cell apoptosis.

Aires V, Brassart B, Carlier A, Scagliarini A, Mandard S, Limagne E, Solary E, Martiny L, Tarpin M, Delmas D.

Mol Nutr Food Res. 2014 Sep;58(9):1785-94. doi: 10.1002/mnfr.201300962. Epub 2014 Jun 30.

24.

Differential protective effects of red wine polyphenol extracts (RWEs) on colon carcinogenesis.

Mazué F, Delmas D, Murillo G, Saleiro D, Limagne E, Latruffe N.

Food Funct. 2014 Apr;5(4):663-70. doi: 10.1039/c3fo60417a.

PMID:
24569685
25.

Potential role of oxidative DNA damage in the impact of PNPLA3 variant (rs 738409 C>G) in hepatocellular carcinoma risk.

Limagne E, Cottet V, Cotte AK, Hamza S, Hillon P, Latruffe N, Delmas D; CiRCE Study Group.

Hepatology. 2014 Sep;60(3):1110-1. doi: 10.1002/hep.27004. Epub 2014 Jul 28. No abstract available.

PMID:
24425147
26.

Importance of lipid microdomains, rafts, in absorption, delivery, and biological effects of resveratrol.

Delmas D, Aires V, Colin DJ, Limagne E, Scagliarini A, Cotte AK, Ghiringhelli F.

Ann N Y Acad Sci. 2013 Jul;1290:90-7. doi: 10.1111/nyas.12177. Review.

PMID:
23855470
27.

Resveratrol metabolites inhibit human metastatic colon cancer cells progression and synergize with chemotherapeutic drugs to induce cell death.

Aires V, Limagne E, Cotte AK, Latruffe N, Ghiringhelli F, Delmas D.

Mol Nutr Food Res. 2013 Jul;57(7):1170-81. doi: 10.1002/mnfr.201200766. Epub 2013 Mar 14.

PMID:
23495229
28.

Resveratrol initiates differentiation of mouse skeletal muscle-derived C2C12 myoblasts.

Kaminski J, Lançon A, Aires V, Limagne E, Tili E, Michaille JJ, Latruffe N.

Biochem Pharmacol. 2012 Nov 15;84(10):1251-9. doi: 10.1016/j.bcp.2012.08.023. Epub 2012 Sep 5.

PMID:
22975027
29.

A moderate red wine intake improves blood lipid parameters and erythrocytes membrane fluidity in post myocardial infarct patients.

Rifler JP, Lorcerie F, Durand P, Delmas D, Ragot K, Limagne E, Mazué F, Riedinger JM, d'Athis P, Hudelot B, Prost M, Lizard G, Latruffe N.

Mol Nutr Food Res. 2012 Feb;56(2):345-51. doi: 10.1002/mnfr.760.

PMID:
22419533
30.

Endocytosis of resveratrol via lipid rafts and activation of downstream signaling pathways in cancer cells.

Colin D, Limagne E, Jeanningros S, Jacquel A, Lizard G, Athias A, Gambert P, Hichami A, Latruffe N, Solary E, Delmas D.

Cancer Prev Res (Phila). 2011 Jul;4(7):1095-106. doi: 10.1158/1940-6207.CAPR-10-0274. Epub 2011 Apr 5.

31.

Transport, stability, and biological activity of resveratrol.

Delmas D, Aires V, Limagne E, Dutartre P, Mazué F, Ghiringhelli F, Latruffe N.

Ann N Y Acad Sci. 2011 Jan;1215:48-59. doi: 10.1111/j.1749-6632.2010.05871.x. Review.

PMID:
21261641
32.

Resveratrol decreases the levels of miR-155 by upregulating miR-663, a microRNA targeting JunB and JunD.

Tili E, Michaille JJ, Adair B, Alder H, Limagne E, Taccioli C, Ferracin M, Delmas D, Latruffe N, Croce CM.

Carcinogenesis. 2010 Sep;31(9):1561-6. doi: 10.1093/carcin/bgq143. Epub 2010 Jul 9.

Supplemental Content

Loading ...
Support Center